Celine Halioua is the founder and CEO of Loyal, a biotech company developing FDA-approved drugs to extend the healthy lifespan of dogs. In this follow-up episode, Celine discusses Loyal’s latest milestones, now with three longevity drugs in development and $150M in funding. This conversation covers the rationale behind building a multi-product biotech company, how she raised a Series B during a brutal fundraising climate, and Celine’s insight into building a mission-driven company culture.
For a deeper dive into the episode, check out Carly's Substack: https://carlymalatskey.substack.com/
Podden och tillhörande omslagsbild på den här sidan tillhör
Carly Malatskey. Innehållet i podden är skapat av Carly Malatskey och inte av,
eller tillsammans med, Poddtoppen.
